

Special Issue

Targeting Tumor Microenvironment in Cancer: Promises and Challenges

Message from the Guest Editors

The tumor microenvironment (TME) is the environment surrounding a tumor, and it plays a critical role in cancer progression. The TME is made up of a variety of cells, including tumor cells, immune cells, and stromal cells. These cells interact with each other in a complex way to create an environment that is favorable for tumor growth and metastasis. Traditional cancer treatments, such as chemotherapy and radiation therapy, can be effective at killing tumor cells. However, these treatments can also damage healthy cells, and they often lead to the recurrence of the cancer. By targeting the TME, it is possible to disrupt the interactions between tumor cells and the other cells in the microenvironment, preventing tumor growth and metastasis. This targeting is achieved via drugs that target specific molecules. Another approach to targeting the TME is to use cell-based therapies, where engineered immune cells could be used to attack tumor cells. This Special Issue will provide an overview of the tumor microenvironment and the different ways to target it. The Special Issue will also discuss the challenges and opportunities associated with TME-targeted therapy.

Guest Editors

Prof. Dr. Ahmed H.K. El-Hashash

Prof. Dr. Hussein Sabit

Dr. Borros Michael Arneth

Deadline for manuscript submissions

closed (20 July 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/181461

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)